[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Denali Therapeutics Inc (DNLI)

Denali Therapeutics Inc (DNLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,607,479
  • Shares Outstanding, K 158,710
  • Annual Sales, $ 0 K
  • Annual Income, $ -512,540 K
  • EBIT $ -547 M
  • EBITDA $ -546 M
  • 60-Month Beta 0.96
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.94

Options Overview Details

View History
  • Implied Volatility 74.16% (+1.30%)
  • Historical Volatility 61.79%
  • IV Percentile 33%
  • IV Rank 19.52%
  • IV High 155.38% on 11/13/25
  • IV Low 54.46% on 08/18/25
  • Expected Move (DTE 35) 1.19 (5.11%)
  • Put/Call Vol Ratio 0.84
  • Today's Volume 363
  • Volume Avg (30-Day) 820
  • Put/Call OI Ratio 0.82
  • Today's Open Interest 14,861
  • Open Int (30-Day) 12,623
  • Expected Range 22.10 to 24.48

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.73
  • Number of Estimates 10
  • High Estimate $-0.67
  • Low Estimate $-0.89
  • Prior Year $-0.72
  • Growth Rate Est. (year over year) -1.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.01 +5.82%
on 07/15/26
27.30 -14.69%
on 07/09/26
-0.20 (-0.85%)
since 06/17/26
3-Month
17.71 +31.51%
on 05/19/26
27.30 -14.69%
on 07/09/26
+2.72 (+13.22%)
since 04/17/26
52-Week
12.58 +85.14%
on 09/22/25
27.30 -14.69%
on 07/09/26
+8.76 (+60.29%)
since 07/17/25

Most Recent Stories

More News
An experimental Alzheimer's drug shows promise targeting a different brain protein, new study shows

An experimental drug might help slow early Alzheimer's disease in a markedly different way than current treatments — by lowering the brain's production of a protein called tau

DNLI : 23.29 (+2.46%)
IONS : 54.39 (-0.48%)
NAMS : 31.68 (+2.03%)
BIIB : 205.99 (-1.40%)
Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier

Denali co-founder and CEO Ryan Watts, Ph.D., to deliver opening plenary address at 2026 AAIC in London on July 12, 2026 Presentation will highlight recent scientific advances and future opportunities...

DNLI : 23.29 (+2.46%)
Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million

Proceeds from transaction to support advancement of Denali’s broad TransportVehicle™-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseases Denali was awarded...

DNLI : 23.29 (+2.46%)
Stocks Settle Higher on Iran Peace Hopes and Tech Strength

The S&P 500 Index ($SPX ) (SPY ) on Friday closed up +0.37%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.58%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.42%. June E-mini S&P...

AMAT : 529.66 (-5.57%)
INTU : 291.09 (-1.26%)
ADI : 375.36 (-1.36%)
DDOG : 258.69 (-1.38%)
MRK : 127.50 (-0.10%)
TXN : 284.02 (-2.47%)
$IUXX : 28,592.66 (-1.49%)
COIN : 157.12 (-2.10%)
ASML : 1,747.58 (-2.09%)
ZNU26 : 109-085s (+0.11%)
ESU26 : 7,497.75s (-1.06%)
QCOM : 171.78 (+0.69%)
Stocks Climb on US-Iran Peace Hopes and Strength in Chipmakers

The S&P 500 Index ($SPX ) (SPY ) today is up +0.50%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.63%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.73%. June E-mini S&P futures (ESM26...

AMAT : 529.66 (-5.57%)
INTU : 291.09 (-1.26%)
ADI : 375.36 (-1.36%)
DDOG : 258.69 (-1.38%)
MRK : 127.50 (-0.10%)
TXN : 284.02 (-2.47%)
$IUXX : 28,592.66 (-1.49%)
ASML : 1,747.58 (-2.09%)
ZNU26 : 109-085s (+0.11%)
ESU26 : 7,497.75s (-1.06%)
QCOM : 171.78 (+0.69%)
IBM : 212.67 (-2.91%)
Stocks Supported by US-Iran Peace Deal Optimism

The S&P 500 Index ($SPX ) (SPY ) today is up +0.54%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.70%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.53%. June E-mini S&P futures (ESM26...

AMAT : 529.66 (-5.57%)
INTU : 291.09 (-1.26%)
ADI : 375.36 (-1.36%)
DDOG : 258.69 (-1.38%)
MRK : 127.50 (-0.10%)
TXN : 284.02 (-2.47%)
$IUXX : 28,592.66 (-1.49%)
ASML : 1,747.58 (-2.09%)
ZNU26 : 109-085s (+0.11%)
MSFT : 393.82 (-1.82%)
ESU26 : 7,497.75s (-1.06%)
QCOM : 171.78 (+0.69%)
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

The Phase 2b LUMA study of BIIB122 in early-stage Parkinson’s disease did not meet its primary or secondary endpoints  Based on data from the Phase 2b LUMA study, Biogen and Denali will discontinue...

DNLI : 23.29 (+2.46%)
BIIB : 205.99 (-1.40%)
Denali Therapeutics Says AVLAYAH Launch Ahead of Expectations After Hunter Syndrome Approval

Denali Therapeutics (NASDAQ:DNLI) is seeing early commercial interest for its first approved drug, AVLAYAH, following its March 24 accelerated approval for Hunter syndrome, Chief Operating Officer and...

DNLI : 23.29 (+2.46%)
Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

FDA approved AVLAYAHâ„¢ (tividenofusp alfa-eknm) for treatment of Hunter syndrome (MPS II) and as first medicine to leverage transferrin receptor to cross blood-brain barrier AVLAYAH launched in U.S....

DNLI : 23.29 (+2.46%)
Denali's First Commercial Quarter Will Show Whether Hunter Syndrome Launch Mechanics Actually Work

Barchart Research What to Expect from DNLI Earnings DNLI Generated May 4, 2026 Current Price $18.67 EPS Estimate $$-0.73 Consensus Rating Strong Buy Average Move 5.31% Denali's First Commercial Quarter...

DNLI : 23.29 (+2.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Denali Therapeutics, a biopharmaceutical company, is developing a wide and innovative portfolio of targeted therapeutic candidates, which are engineered to cross the blood-brain barrier for neurodegenerative diseases. It has 5 clinical-stage programs, a leucine-rich repeat kinase 2 inhibitor program...

See More

Key Turning Points

3rd Resistance Point 25.09
2nd Resistance Point 24.44
1st Resistance Point 23.87
Last Price 23.29
1st Support Level 22.65
2nd Support Level 22.00
3rd Support Level 21.43

See More

52-Week High 27.30
Last Price 23.29
Fibonacci 61.8% 21.68
Fibonacci 50% 19.94
Fibonacci 38.2% 18.20
52-Week Low 12.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.